

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

FIRST NAMED INVENTOR
Sudhir V. Shah

[illegible]

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2629.1003-011		APPLICATION NO. 10/820,537	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION				FILING DATE April 8, 2004	
July 20, 2004 (Use several sheets if necessary)				EXAMINER Not Assigned	
CONFIRMATION NO. 8841				GROUP 1654	

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
<i>W</i>	AE	4,684,482	08-04-1987	Green
<i>W</i>	AF	5,047,329	09-10-1991	Suzuki
<i>W</i>	AG	6,206,849 B1	03-27-2001	Martin <i>et al.</i>
<i>W</i>	AH	6,383,817 B2	05-07-2002	Schwartz
<i>W</i>	AI	6,589,966 B1	07-08-2003	Torti <i>et al.</i>
	AJ	6,706,287 B2	03-16-2004	Ranganathan <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
<i>W</i>	AL2	WO 00/54784	09-21-2000	Aripkodzhaeva		X
<i>W</i>	AM2	JP 05000949 A	01-08-1993	Santen Pharmaceuticals Co., Ltd Dai Ichi Seiyaku Co., Ltd.	X (Abstract)	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>W</i>	AW5	Fernández-Real, J.M., <i>et al.</i> , "Cross-Talk Between Iron Metabolism and Diabetes," <i>Diabetes</i> , 51:2348-2354, 2002
<i>W</i>	AX5	Nitenberg, A., <i>et al.</i> , "Coronary Microvascular Adaptation to Myocardial Metabolic Demand Can Be Restored by Inhibition of Iron-Catalyzed Formation of Oxygen Free Radicals in Type 2 Diabetic Patients," <i>Diabetes</i> , 51:813-818, 2002

EXAMINER

DATE CONSIDERED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

FIRST NAMED INVENTOR
Sudhir V. Shah

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
<i>M</i>	AA	5,047,421	09-10-91	Green
<i>H</i>	AB	5,721,209	02-24-98	Horwitz <i>et al.</i>
<i>M</i>	AC	5,811,127	09-22-98	Milstein <i>et al.</i>
<i>W</i>	AD	5,091,180	02-25-92	Walker <i>et al.</i>

FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

09/07/2024

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO.

2629.1003-011

FIRST NAMED INVENTOR

Sudhir V. Shah

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Sumboonnanda, A., <i>et al.</i> , "Renal tubular function in β -thalassemia", <i>Pediatr Nephrol</i> , 12:280-283.
AS	Ong-ajyooth, L., <i>et al.</i> , "Renal Function in Adult Beta-Thalassemia/Hb E Disease", <i>Nephron</i> , 78:156-161 (1998).
AT	Guasch, A., <i>et al.</i> , "Evidence that Microdeletions in the α Globin Gene Protect Against the Development of Sick Cell Glomerulopathy in Humans", <i>J Am Soc Nephrol</i> , 10:1014-1019 (1999).
AU	Loebstein, R., <i>et al.</i> , "Diabetic Nephropathy in Hypertransfused Patients with β -Thalassemia", <i>Diabetes Care</i> , 21(8):1306-1309 (1998).
AV	Ongajyooth, L., <i>et al.</i> , "Glomerulonephritis in β -thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", <i>J Med Assoc Thai</i> , 78(3):119-126 (1995).
AW	Aoki, R.Y., <i>et al.</i> , "Microalbuminuria in Sick Cell Disease", <i>Brazilian J Med Biol Res</i> , 23:1103-1106 (1990).
AX	Katopodis, K.P., <i>et al.</i> , "Renal Abnormalities in Patients with Sick Cell-Beta Thalassemia", <i>Journal of Nephrology</i> , 10(3):163-167 (1997).
AY	Pham, P.-T.T., <i>et al.</i> , "Renal abnormalities in sickle cell disease", <i>Kidney International</i> , 57:1-8 (2000).
AZ	Kontoghiorghe, G.J., <i>et al.</i> , "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", <i>Inorganica Chimica Acta</i> , 136:L11-L12 (1987).
AR2	Falk, R.J., <i>et al.</i> , "Prevalence and Pathologic Features of Sick Cell Nephropathy and Response to Inhibition of Angiotensin-Converting Enzyme", <i>The New England Journal of Medicine</i> , 326(14):910-915 (1992).
AS2	Guasch, A., <i>et al.</i> , "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", <i>Kidney International</i> , 51:826-833 (1997).
AT2	Cianciulli, P., <i>et al.</i> , "Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy", <i>Kidney International</i> , 46:467-470 (1994).
AU2	Ueda, N., <i>et al.</i> , "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", <i>Kidney International</i> , 49:370-373 (1996).


EXAMINER

DATE CONSIDERED

09/07/2004

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION April 8, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-011 FIRST NAMED INVENTOR Sudhir V. Shah
---	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
W	AV2	Savill, J., <i>et al.</i> , "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2 nd ed., pages 404-439, eds., Davidson, A.M., <i>et al.</i> , Oxford Univ. Press (1998).
N	AW2	Ueda, N., <i>et al.</i> , "In Vivo Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", <i>Kidney: A Current Survey of World Literature</i> , 6:143-146 (1997).
a	AX2	Boyce, N.W., <i>et al.</i> , "Hydroxyl radical mediation of immune renal injury by desferrioxamine", <i>Kidney International</i> , 30:813-817 (1986).
N	AY2	Baliga, R., <i>et al.</i> , "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", <i>J Am Soc Nephrol</i> , 7(8):1183-1188 (1996).
H	AZ2	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", <i>The American Physiological Society</i> , F337-F344(1988).
N	AR3	Thakur, V., <i>et al.</i> , "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", <i>Kidney International</i> , 34:494-499 (1988).
N	AS3	Nankivell, B.J., <i>et al.</i> , "The Role of Tubular Iron Accumulation in the Remnant Kidney", <i>J Am Soc Nephrol</i> , 4(8):1598-1607 (1994).
N	AT3	Alfrey, A.C., <i>et al.</i> , "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", <i>Kidney International</i> , 36:753-759 (1989).
N	AU3	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2 nd ed., pages 1749-1788, eds., Davidson, A.M., <i>et al.</i> , Oxford Univ. Press (1998).
N	AV3	Howard R.L., <i>et al.</i> , "Urinary albumin, transferrin and iron excretion in diabetic patients", <i>International Society of Nephrology</i> , 40:923-926 (1991).
N	AW3	Olivieri, N.F., <i>et al.</i> , "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", <i>The New England Journal of Medicine</i> , 918-922 (1995).
N	AX3	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", <i>American Journal of Physiology</i> , 263(4):F637-F641 (1992).

EXAMINER 	DATE CONSIDERED 09/07/2007
--	-------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION April 8, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-011 FIRST NAMED INVENTOR Sudhir V. Shah
---	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
W	AY3	Wu, Z-L, <i>et al.</i> , "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," <i>Renal Failure</i> , 16(4): 471-480 (1994).
a	AZ3	Baliga, R., <i>et al.</i> , "In Vitro and In Vivo Evidence Suggesting a Role for Iron in Cistaplin-induced Nephrotoxicity," <i>Kidney International</i> , 53(2): 394-401 (February 1998).
N	AR4	Harris, D., <i>et al.</i> , "Mitochondrial Function in Rat Renal Cortex in REsponse to Proteinuria and Iron," <i>Clinical and Experimental Pharmacology and Physiology</i> 24:916-922 (December 1997).
F	AS4	Walker, P.D., <i>et al.</i> , "Evidence Suggesting a Role for Hydroxyl Radical in Gentamicin-Induced Acute Renal Failure in Rats," <i>J Clin Invest</i> 81:334-341 (1988).
N	AT4	Shah, S.V., <i>et al.</i> , "Evidence Suggesting a Role for Hydroxyl Radical in Glycerol-Induced Acute Renal Failure," <i>Am J Physiol</i> 255, (Renal Fluid Electrolyte Physiol. 24):F438-F443 (1988).
N	AU4	Baliga, R., <i>et al.</i> , "Increase in Bleomycin-Detectable Iron in Ischaemia/Reperfusion Injury to Rat Kidneys," <i>Biochem J</i> 291(3):901-905 (1993).
N	AV4	Kontoghiorghe, G.J., <i>et al.</i> , "Studies of Aluminium Mobilization in Renal Dialysis Patients Using the Oral Chelator 1,2-Dimethyl-3-hydroxypyrid-4-one," <i>Arzneim-Forsch/Drug Res.</i> 44(1):522-526 (1994).
N	AW4	Baliga, R., <i>et al.</i> , "Oxidant Mechanisms in Toxic Acute Renal Failure," <i>Drug Metabolism Reviews</i> 31(4):971-991 (1999).
N	AX4	Walker, P.D., <i>et al.</i> , "Gentamicin Enhanced Production of Hydrogen Peroxide by Renal Cortical Mitochondria," <i>Am J Physiol</i> 253:C495-C499 (1987).
N	AY4	Walker, P.D., <i>et al.</i> , "Hydrogen Peroxide Cytotoxicity in LLC-PK ₁ Cells: A Role for Iron," <i>Kidney Int</i> 40:891-898 (1991).
N	AZ4	Abul-Ezz, S.R., <i>et al.</i> , "Role of Glutathione in an Animal Model of Myoglobinuric Acute Renal Failure," <i>Proc Natl Acad Sci</i> 88:9833-9837 (1991).
N	AR5	Ueda, N., <i>et al.</i> , "Gentamicin-Induced Mobilization of Iron from Renal Cortical Mitochondria," <i>Am J Physiol</i> 265(3 Pt. 2):F435-F439 (1993).
N	AS5	Baliga, R., <i>et al.</i> , "Evidence for Cytochrome P-450 as a Source of Catalytic Iron in Myoglobinuric Acute Renal Failure," <i>Kidney Int</i> 49:362-369 (1996).

EXAMINER 	DATE CONSIDERED 09/07/2004
--	----------------------------

April 8, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO.

2629.1003-011

FIRST NAMED INVENTOR

Sudhir V. Shah

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

09/07/2004